162 related articles for article (PubMed ID: 9134643)
1. Inhibition rather than enhancement of hemostatic system activation during initiation of oral anticoagulant treatment.
Kyrle PA; Brockmeier J; Weltermann A; Eichinger S; Speiser W; Lechner K; Eichler HG
Thromb Haemost; 1997 Apr; 77(4):685-9. PubMed ID: 9134643
[TBL] [Abstract][Full Text] [Related]
2. Relationship between international normalized ratio values, vitamin K-dependent clotting factor levels and in vivo prothrombin activation during the early and steady phases of oral anticoagulant treatment.
D'Angelo A; Della Valle P; Crippa L; Fattorini A; Pattarini E; Viganò D'Angelo S
Haematologica; 2002 Oct; 87(10):1074-80. PubMed ID: 12368163
[TBL] [Abstract][Full Text] [Related]
3. Changes in molecular markers of hemostatic and fibrinolytic activation under various sampling conditions using vacuum tube samples from healthy volunteers.
Omote M; Asakura H; Takamichi S; Shibayama M; Yoshida T; Kadohira Y; Maekawa M; Yamazaki M; Morishita E; Nakao S; Wada T
Thromb Res; 2008; 123(2):390-5. PubMed ID: 18579183
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the effects of different low molecular weight heparins on the hemostatic system activation in vivo in man.
Wolzt M; Eder M; Weltermann A; Entlicher J; Eichler HG; Kyrle PA
Thromb Haemost; 1997 Aug; 78(2):876-9. PubMed ID: 9268188
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of thrombin generation by the oral direct thrombin inhibitor ximelagatran in shed blood from healthy male subjects.
Sarich TC; Eriksson UG; Mattsson C; Wolzt M; Frison L; Fager G; Gustafsson D
Thromb Haemost; 2002 Feb; 87(2):300-5. PubMed ID: 11858491
[TBL] [Abstract][Full Text] [Related]
6. Levels of prothrombin fragment F1+2 in patients with hyperhomocysteinemia and a history of venous thromboembolism.
Kyrle PA; Stümpflen A; Hirschl M; Bialonczyk C; Herkner K; Speiser W; Weltermann A; Kaider A; Pabinger I; Lechner K; Eichinger S
Thromb Haemost; 1997 Nov; 78(5):1327-31. PubMed ID: 9408013
[TBL] [Abstract][Full Text] [Related]
7. Prospective evaluation of hemostatic system activation and thrombin potential in healthy pregnant women with and without factor V Leiden.
Eichinger S; Weltermann A; Philipp K; Hafner E; Kaider A; Kittl EM; Brenner B; Mannhalter C; Lechner K; Kyrle PA
Thromb Haemost; 1999 Oct; 82(4):1232-6. PubMed ID: 10544904
[TBL] [Abstract][Full Text] [Related]
8. Hemostatic effects of oral contraceptives in women who developed deep-vein thrombosis while using oral contraceptives.
Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Koster T; Bertina RM; Vandenbroucke JP
Thromb Haemost; 1998 Sep; 80(3):382-7. PubMed ID: 9759614
[TBL] [Abstract][Full Text] [Related]
9. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study.
Middeldorp S; Meijers JC; van den Ende AE; van Enk A; Bouma BN; Tans G; Rosing J; Prins MH; Büller HR
Thromb Haemost; 2000 Jul; 84(1):4-8. PubMed ID: 10928461
[TBL] [Abstract][Full Text] [Related]
10. L-Asparaginase and the effect of age on coagulation and fibrinolysis in childhood acute lymphoblastic leukemia.
Appel IM; Hop WC; van Kessel-Bakvis C; Stigter R; Pieters R
Thromb Haemost; 2008 Aug; 100(2):330-7. PubMed ID: 18690355
[TBL] [Abstract][Full Text] [Related]
11. Recurrent coumarin-induced skin necrosis in a patient with an acquired functional protein C deficiency.
Teepe RG; Broekmans AW; Vermeer BJ; Nienhuis AM; Loeliger EA
Arch Dermatol; 1986 Dec; 122(12):1408-12. PubMed ID: 3789774
[TBL] [Abstract][Full Text] [Related]
12. Treatment of coumarin-induced skin necrosis with a monoclonal antibody purified protein C concentrate.
Schramm W; Spannagl M; Bauer KA; Rosenberg RD; Birkner B; Linnau Y; Schwarz HP
Arch Dermatol; 1993 Jun; 129(6):753-6. PubMed ID: 8507079
[TBL] [Abstract][Full Text] [Related]
13. Plasma coagulation markers in patients with solid tumors and venous thromboembolic disease receiving oral anticoagulation therapy.
Sallah S; Husain A; Sigounas V; Wan J; Turturro F; Sigounas G; Nguyen NP
Clin Cancer Res; 2004 Nov; 10(21):7238-43. PubMed ID: 15534097
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy-induced activation of hemostasis: effect of a low molecular weight heparin (dalteparin sodium) on plasma markers of hemostatic activation.
Weitz IC; Israel VK; Waisman JR; Presant CA; Rochanda L; Liebman HA
Thromb Haemost; 2002 Aug; 88(2):213-20. PubMed ID: 12195692
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous and systemic effects of varying doses of brown recluse spider venom in a rabbit model.
McGlasson DL; Harroff HH; Sutton J; Dick E; Elston DM
Clin Lab Sci; 2007; 20(2):99-105. PubMed ID: 17557708
[TBL] [Abstract][Full Text] [Related]
16. Thrombin generation and coagulation factor activities: evaluation and comparison with the international normalized ratio.
Christensen TD; Jensen C; Larsen TB; Christiansen K; Sørensen B
Blood Coagul Fibrinolysis; 2009 Jul; 20(5):358-65. PubMed ID: 19417631
[TBL] [Abstract][Full Text] [Related]
17. The effect of very-low-dose warfarin on markers of hypercoagulation in metastatic breast cancer: results from a randomized trial.
Falanga A; Levine MN; Consonni R; Gritti G; Delaini F; Oldani E; Julian JA; Barbui T
Thromb Haemost; 1998 Jan; 79(1):23-7. PubMed ID: 9459316
[TBL] [Abstract][Full Text] [Related]
18. Hemostasis during normal pregnancy and puerperium.
Hellgren M
Semin Thromb Hemost; 2003 Apr; 29(2):125-30. PubMed ID: 12709915
[TBL] [Abstract][Full Text] [Related]
19. Plasma protein oxidation is associated with an increase of procoagulant markers causing an imbalance between pro- and anticoagulant pathways in healthy subjects.
De CR; Rocca B; Marchioli R; Landolfi R
Thromb Haemost; 2002 Jan; 87(1):58-67. PubMed ID: 11848457
[TBL] [Abstract][Full Text] [Related]
20. Activation of coagulation during hemodialysis: effect of blood lines alone and whole extracorporeal circuit.
Lucchi L; Ligabue G; Marietta M; Delnevo A; Malagoli M; Perrone S; Stipo L; Grandi F; Albertazzi A
Artif Organs; 2006 Feb; 30(2):106-10. PubMed ID: 16433843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
